MIC

BIOLOGICAL2 trials

Sponsors

TolerogenixX GmbH

Conditions

Kidney TransplantationLiving donor kidney transplantation

Phase 2

Clinical Trial With Donor Modified Immune Cells in Living Donor Kidney Transplantation

RecruitingNCT05365672

TolerogenixX GmbHKidney Transplantation

Start: 2022-05-04End: 2028-12-31Target: 126Updated: 2025-04-11

An open, randomized-controlled, multi-center phase-II clinical trial of individualized immunosuppression with intravenously administered donor modified immune cells (MIC) compared to standard-of-care in living donor kidney transplantation

RecruitingCTIS2024-513446-12-00

TolerogenixX GmbHLiving donor kidney transplantation

Start: 2022-05-03Target: 126Updated: 2025-07-08

Related Papers

Five-year follow-up of a phase I trial of donor-derived modified immune cell infusion in kidney transplantation

Frontiers in Immunology2023-07-077 citations

Individualised immunosuppression with intravenously administered donor-derived modified immune cells compared with standard of care in living donor kidney transplantation (TOL-2 Study): protocol for a multicentre, open-label, phase II, randomised controlled trial

BMJ Open2022-11-016 citations